AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22313587 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (C22)
Number of subjects: 18
Study 22313587 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid (OA)
Number of subjects: 18
Study 22313587 — intervention group
Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 18
Study 16713501 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration study with feedback and information about harmful effects
Number of subjects: 59
Study 16713501 — intervention group
Group type: COMPARATOR
Intervention: Alcohol administration study
Number of subjects: 59
Study 12898439 — intervention group
Group type: COMPARATOR
Intervention: intermittent subcutaneous IL-2 and placebo
Number of subjects: 0
Study 12898439 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent subcutaneous IL-2 and prednisone
Number of subjects: 0
Study 12898439 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent prednisone
Number of subjects: 0
Study 12898439 — intervention group
Group type: COMPARATOR
Intervention: intermittent placebo
Number of subjects: 0
Study 10371876 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc citrate dentifrice (2% zinc citrate and 0.76% sodium monofluorophosphate in a silica base)
Number of subjects: 99
Study 10371876 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice (0.76% sodium monofluorophosphate in a silica base)
Number of subjects: 99
Study 10371876 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc citrate dentifrice
Number of subjects: 99
Study 10371876 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 99
Study 7602215 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT + BCG (rifampin once a month, clofazimine and dapsone daily, BCG intradermally 0.1 mg/dose)
Number of subjects: 36
Study 7602215 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT + Mycobacterium w (same MDT with 2 x 10(8) killed bacilli/dose i.d.)
Number of subjects: 36
Study 7602215 — intervention group
Group type: COMPARATOR
Intervention: MDT alone (control group)
Number of subjects: 36
Study 2772038 — intervention group
Group type: EXPERIMENTAL
Intervention: NO-VAL Group
Number of subjects: 27
Study 2772038 — intervention group
Group type: COMPARATOR
Intervention: CONT Group
Number of subjects: 27
Study 799927 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 4000
Study 799927 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4000
Study 31009801 — intervention group
Group type: EXPERIMENTAL
Intervention: Inertial measurement units (IMUs)
Number of subjects: 26
Study 31864519 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized rehabilitation and chiropractic treatment
Number of subjects: 13
Study 31864519 — intervention group
Group type: COMPARATOR
Intervention: Individualized rehabilitation alone
Number of subjects: 13
Study 28731004 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal-directed mobilization using the Surgical Optimal Mobilization Score (SOMS) algorithm.
Number of subjects: 200
Study 28731004 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal-directed mobilization protocol.
Number of subjects: 200
Study 28731004 — intervention group
Group type: COMPARATOR
Intervention: Control group mobilization according to individual centre’s standard protocols.
Number of subjects: 200
Study 25343537 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated water-based exercise (HEx)
Number of subjects: 15
Study 25343537 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based exercise (LEx)
Number of subjects: 15
Study 23516146 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural-educational sleep intervention
Number of subjects: 246
Study 23516146 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 246
Study 22093629 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with platinum
Number of subjects: 162
Study 22093629 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome combined with platinum
Number of subjects: 162
Study 18641526 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement twice a week (Group 1)
Number of subjects: 30
Study 18641526 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement once a week (Group 2)
Number of subjects: 30
Study 18641526 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement once every 2 weeks (Group 3)
Number of subjects: 30
Study 18641526 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 30
Study 16875473 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC (10 mg/mL) injected weekly for 8 weeks
Number of subjects: 69
Study 16875473 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC (40 mg/mL) + 5-FU (50 mg/mL) injected weekly for 8 weeks
Number of subjects: 69
Study 16875473 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC (40 mg/mL) + 5-FU (50 mg/mL) injected weekly for 8 weeks + PDL (5-7.5 J/cm2) at 1st, 4th, and 8th weeks
Number of subjects: 69
Study 12621503 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells (PBSC)
Number of subjects: 213
Study 12621503 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow (BM)
Number of subjects: 213
Study 10718774 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg, 20 mg, and 10 + 20 mg tablets; solution administered once daily for 2 weeks
Number of subjects: 26
Study 10718774 — intervention group
Group type: COMPARATOR
Intervention: Tablets
Number of subjects: 26
Study 10718774 — intervention group
Group type: COMPARATOR
Intervention: Solution
Number of subjects: 26
Study 8653389 — intervention group
Group type: EXPERIMENTAL
Intervention: Audible speech
Number of subjects: 30
Study 8653389 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent speech (internal speech)
Number of subjects: 30
Study 8653389 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 30
Study 1327051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (10 mg)
Number of subjects: 6
Study 1327051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3855338 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty
Number of subjects: 0
Study 3855338 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical trabeculectomy
Number of subjects: 0
Study 3855338 — intervention group
Group type: COMPARATOR
Intervention: Medicine
Number of subjects: 0
Study 3855338 — intervention group
Group type: COMPARATOR
Intervention: Laser
Number of subjects: 0
Study 29291550 — intervention group
Group type: EXPERIMENTAL
Intervention: EtG screening
Number of subjects: 162
Study 29291550 — intervention group
Group type: COMPARATOR
Intervention: Ethanol screening
Number of subjects: 162
Study 28453765 — intervention group
Group type: EXPERIMENTAL
Intervention: mongersen (Smad7 antisense oligonucleotide)
Number of subjects: 95
Study 28453765 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 95
Study 28453765 — intervention group
Group type: EXPERIMENTAL
Intervention: Smad7 over-expressing NCM460 cells
Number of subjects: 95
Study 28453765 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-β1
Number of subjects: 95
Study 26641456 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise countermeasure during 8 weeks of bed rest
Number of subjects: 20
Study 26641456 — intervention group
Group type: COMPARATOR
Intervention: Strict bed rest without exercise
Number of subjects: 20
Study 22971113 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer health worker (PHW) intervention
Number of subjects: 0
Study 22971113 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth (mobile phone) support intervention
Number of subjects: 0
Study 20970870 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0
Study 20970870 — intervention group
Group type: COMPARATOR
Intervention: NPH
Number of subjects: 0
Study 18468323 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement on untreated zirconia copings
Number of subjects: 140
Study 18468323 — intervention group
Group type: COMPARATOR
Intervention: Sandblasted zirconia copings
Number of subjects: 140
Study 18468323 — intervention group
Group type: COMPARATOR
Intervention: Untreated alumina copings
Number of subjects: 140
Study 18468323 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass pearls on zirconia copings
Number of subjects: 140
Study 18468323 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink II with alumina copings
Number of subjects: 140
Study 16563204 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Core Schema Scales (BCSS)
Number of subjects: 1006
Study 16563204 — intervention group
Group type: EXPERIMENTAL
Intervention: BCSS
Number of subjects: 1006
Study 14584871 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage full-mouth scaling and root planing (FMSRP) plus amoxicillin/clavulanic acid 875 mg (G1)
Number of subjects: 30
Study 14584871 — intervention group
Group type: COMPARATOR
Intervention: Only FMSRP (G2)
Number of subjects: 30
Study 11469284 — intervention group
Group type: EXPERIMENTAL
Intervention: Early occupational therapy intervention, given weekly at home from six months to 12 months.
Number of subjects: 100
Study 11469284 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention (control) group.
Number of subjects: 100
Study 10211012 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg
Number of subjects: 90
Study 10211012 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg
Number of subjects: 90
Study 10211012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 7948562 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (600 mg/d)
Number of subjects: 24
Study 7948562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3252772 — intervention group
Group type: EXPERIMENTAL
Intervention: Students (intervention group)
Number of subjects: 44
Study 3252772 — intervention group
Group type: COMPARATOR
Intervention: Children and elderly (control group)
Number of subjects: 44
Study 3252772 — intervention group
Group type: COMPARATOR
Intervention: Temperature of water at 37 degrees C
Number of subjects: 44
Study 3252772 — intervention group
Group type: COMPARATOR
Intervention: Surface anaesthesia of tongue and palate
Number of subjects: 44
Study 3252772 — intervention group
Group type: COMPARATOR
Intervention: Sipping vs. gulping
Number of subjects: 44
Study 3252772 — intervention group
Group type: COMPARATOR
Intervention: Time taken for water to enter the mouth
Number of subjects: 44
Study 31981517 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy with CADe system
Number of subjects: 962
Study 31981517 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy with sham system
Number of subjects: 962
Study 29528792 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (75 mg twice daily) plus dacarbazine (1,000 mg/m2 intravenously on day 1 of every 21-day cycle)
Number of subjects: 129
Study 29528792 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus dacarbazine (1,000 mg/m2 intravenously on day 1 of every 21-day cycle)
Number of subjects: 129
Study 29528792 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib plus dacarbazine
Number of subjects: 129
Study 29528792 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus dacarbazine
Number of subjects: 129
Study 28126333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg/day
Number of subjects: 376
Study 28126333 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based chemotherapy (cisplatin 75 mg/m2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m2 every 3 weeks for four cycles followed by maintenance pemetrexed)
Number of subjects: 376
Study 26432173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 165
Study 26432173 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 165
Study 26432173 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy process at the end stage
Number of subjects: 165
Study 23239676 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (80 mg · kg‐1 BM · d‐1)
Number of subjects: 16
Study 23239676 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 16
Study 23239676 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine
Number of subjects: 16
Study 23239676 — intervention group
Group type: COMPARATOR
Intervention: Beta-alanine and Placebo
Number of subjects: 16
Study 21623838 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic VR simulator training using microcomputed tomography tooth models
Number of subjects: 32
Study 21623838 — intervention group
Group type: COMPARATOR
Intervention: Conventional training using extracted teeth in a phantom head
Number of subjects: 32
Study 18287411 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol injection (PEI) + radiofrequency ablation (n = 50)
Number of subjects: 142
Study 18287411 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation alone (n = 114)
Number of subjects: 142
Study 18287411 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk radiofrequency ablation (n = 50)
Number of subjects: 142
Study 18287411 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation of non-high-risk tumors (n = 44)
Number of subjects: 142
Study 18287411 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk radiofrequency ablation + PEI (n = 50)
Number of subjects: 142
Study 18287411 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high-risk tumors
Number of subjects: 142
Study 18287411 — intervention group
Group type: COMPARATOR
Intervention: Patients without high-risk tumors
Number of subjects: 142
Study 16541860 — intervention group
Group type: EXPERIMENTAL
Intervention: Penetration needling (Yintang (EX‐HN 3)‐through‐Bigen, Sibai (ST 2)‐through‐Bigen, Yingxiang (LI 20)‐through‐Bigen)
Number of subjects: 120
Study 16541860 — intervention group
Group type: COMPARATOR
Intervention: Oral Biyankang, 4 tablets each time, 3 times daily
Number of subjects: 120
Study 12506149 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysporin Triple antibiotic ointment
Number of subjects: 169
Study 12506149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 10503691 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing 0.32‐1.1% AA and 0.24‐0.75% DHA
Number of subjects: 4
Study 10503691 — intervention group
Group type: COMPARATOR
Intervention: Formula without AA and DHA (Preemie SMA)
Number of subjects: 4
Study 10503691 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk with fortifier
Number of subjects: 4
Study 8944697 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenzepine (selective M1-receptor antagonist)
Number of subjects: 0
Study 8944697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2021851 — intervention group
Group type: EXPERIMENTAL
Intervention: Suturing
Number of subjects: 1004
Study 2021851 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapling
Number of subjects: 1004
Study 6758743 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (twice daily dosage)
Number of subjects: 10
Study 31301436 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 60
Study 31301436 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 60
Study 28355960 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention
Number of subjects: 202
Study 28355960 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 202
Study 26299215 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC‐based educational and feedback intervention including a lecture, access to a mobile app, and individualized feedback reports.
Number of subjects: 0
Study 26299215 — intervention group
Group type: COMPARATOR
Intervention: No education on TTE appropriate use (usual practice).
Number of subjects: 0
Study 24075621 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone plus prednisone
Number of subjects: 1088
Study 24075621 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus prednisone
Number of subjects: 1088
Study 21417810 — intervention group
Group type: EXPERIMENTAL
Intervention: YPET (yogic prana energization technique)
Number of subjects: 30
Study 21417810 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional plaster of paris immobilization)
Number of subjects: 30
Study 19104413 — intervention group
Group type: EXPERIMENTAL
Intervention: ALG-induction, CsA, and prednisone
Number of subjects: 123
Study 19104413 — intervention group
Group type: COMPARATOR
Intervention: CsA, prednisone, and azathioprine
Number of subjects: 123
Study 16579257 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrestricted weightbearing (UWB) combined with intensive physiotherapy
Number of subjects: 36
Study 16579257 — intervention group
Group type: COMPARATOR
Intervention: Partial weightbearing (PWB) for 3 months combined with a short self‐training program
Number of subjects: 36
Study 16579257 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 12929017 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic duct guide wire placement
Number of subjects: 53
Study 12929017 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheter
Number of subjects: 53
Study 11006057 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Belief Model (HBM) elements
Number of subjects: 3648
Study 11006057 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and health variables
Number of subjects: 3648
Study 8852159 — intervention group
Group type: EXPERIMENTAL
Intervention: X-Prep with a less restrictive diet and one enema
Number of subjects: 140
Study 8852159 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 140
Study 1987708 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of cryopreserved donor-specific bone marrow
Number of subjects: 57
Study 1987708 — intervention group
Group type: COMPARATOR
Intervention: Quadruple immunosuppression (MALG, cyclosporin, azathioprine, prednisone) with no marrow transfusion
Number of subjects: 57
Study 6134180 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual withdrawal of diazepam over 3 months by stepwise reduction.
Number of subjects: 41
Study 6134180 — intervention group
Group type: COMPARATOR
Intervention: Immediate withdrawal (double-blind procedure).
Number of subjects: 41
Study 6134180 — intervention group
Group type: COMPARATOR
Intervention: Delayed withdrawal (after 8 weeks, double-blind procedure).
Number of subjects: 41
Study 2870640 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 336
Study 2870640 — intervention group
Group type: COMPARATOR
Intervention: Clorazepate
Number of subjects: 336
Study 31594196 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy at -110°C with exercise therapy
Number of subjects: 92
Study 31594196 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy at -60°C with exercise therapy
Number of subjects: 92
Study 31594196 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy alone
Number of subjects: 92
Study 29609596 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional learning approach
Number of subjects: 40
Study 29609596 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning approach
Number of subjects: 40
Study 24534884 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular consumption of pork (up to 1 kg/week)
Number of subjects: 49
Study 24534884 — intervention group
Group type: COMPARATOR
Intervention: Regular consumption of beef (up to 1 kg/week)
Number of subjects: 49
Study 24534884 — intervention group
Group type: COMPARATOR
Intervention: Regular consumption of chicken (up to 1 kg/week)
Number of subjects: 49
Study 23321178 — intervention group
Group type: EXPERIMENTAL
Intervention: Transareola single‐site endoscopic thyroidectomy (TASSET)
Number of subjects: 48
Study 23321178 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive video‐assisted thyroidectomy (MIVAT)
Number of subjects: 48
Study 20416951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract extraction by phacoemulsification
Number of subjects: 6107
Study 20416951 — intervention group
Group type: EXPERIMENTAL
Intervention: Preintervention VA and negative surgical complexity
Number of subjects: 6107
Study 20416951 — intervention group
Group type: EXPERIMENTAL
Intervention: Preintervention visual function and expected postintervention VA
Number of subjects: 6107
Study 17311054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI diet
Number of subjects: 14
Study 17311054 — intervention group
Group type: COMPARATOR
Intervention: High GI diet
Number of subjects: 14
Study 15968892 — intervention group
Group type: EXPERIMENTAL
Intervention: tcPO2 measurement before amputation
Number of subjects: 56
Study 15968892 — intervention group
Group type: EXPERIMENTAL
Intervention: tcPO2 values between 25 and 36 mm Hg
Number of subjects: 56
Study 15968892 — intervention group
Group type: EXPERIMENTAL
Intervention: tcPO2 threshold value
Number of subjects: 56
Study 12875346 — intervention group
Group type: EXPERIMENTAL
Intervention: Current oral suspension
Number of subjects: 0
Study 12875346 — intervention group
Group type: EXPERIMENTAL
Intervention: Former oral suspension
Number of subjects: 0
Study 10505695 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentanoic acid (EPA) at a dose of 1800 mg daily for 3 months
Number of subjects: 38
Study 10505695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 7559196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg bd iv)
Number of subjects: 100
Study 7559196 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (ceftazidime 1 g bd iv, ampicillin 500 mg qds iv, metronidazole 500 mg tds iv)
Number of subjects: 100
Study 1771312 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitization by autologous saliva
Number of subjects: 44
Study 1771312 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (Control)
Number of subjects: 44
Study 7124839 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin-gentamicin
Number of subjects: 0
Study 7124839 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole-placebo
Number of subjects: 0